1Suzuki, T, Remington, G, Mulsant, BH, Uchida, H, Rajji, TK, Graff-Guerrero, A, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res 2012; 197: 1–6.
2Kennedy, JL, Altar, CA, Taylor, DL, Degtiar, I, Hornberger, JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 2014; 29: 63–76.
3Gillespie, AL, Samanaite, R, Mill, J, Egerton, A, MacCabe, JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry 2017; 17: 12.
4Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31–41.
5Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481–5.
6Shah, P, Iwata, Y, Plitman, E, Brown, EE, Caravaggio, F, Kim, J, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. Psychiatry Res 2018; 268: 114–22.
7National Collaborating Centre for Mental Health. Psychosis and Schizophrenia in Adults: Treatment and Management. National Collaborating Centre for Mental Health, 2014.
8Wimberley, T, Stovring, H, Sorensen, HJ, Horsdal, HT, MacCabe, JH, Gasse, C. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry 2016; 3: 358–66.
9Kim, JS, Park, CM, Choi, JA, Park, E, Tchoe, HJ, Choi, M, et al. The association between season of birth, age at onset, and clozapine use in schizophrenia. Acta Psychiatr Scand 2017; 136: 445–54.
10Frank, J, Lang, M, Witt, SH, Strohmaier, J, Rujescu, D, Cichon, S, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol Psychiatry 2015; 20: 150–1.
11Wimberley, T, Gasse, C, Meier, SM, Agerbo, E, MacCabe, JH, Horsdal, HT. Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia. Schizophr Bull 2017; 43: 1064–9.
12Martin, AK, Mowry, B. Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia. Psychol Med 2016; 46: 469–76.
13Ruderfer, DM, Charney, AW, Readhead, B, Kidd, BA, Kahler, AK, Kenny, PJ, et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry 2016; 3: 350–7.
14Lynham, AJ, Hubbard, L, Tansey, KE, Hamshere, ML, Legge, SE, Owen, MJ, et al. Examining cognition across the bipolar/schizophrenia diagnostic spectrum. J Psychiatry Neurosci 2018; 43: 245–53.
15Pardiñas, AF, Holmans, P, Pocklington, AJ, Escott-Price, V, Ripke, S, Carrera, N, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet 2018; 50: 381–9.
16Howie, BN, Donnelly, P, Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529.
17Huang, J, Howie, B, McCarthy, S, Memari, Y, Walter, K, Min, JL, et al. Improved imputation of low-frequency and rare variants using the UK10 K haplotype reference panel. Nat Commun 2015; 6: 8111.
18Wray, NR, Lee, SH, Mehta, D, Vinkhuyzen, AA, Dudbridge, F, Middeldorp, CM. Research review: polygenic methods and their application to psychiatric traits. J Child Psychol Psychiatry 2014; 55: 1068–87.
19Rees, E, Walters, JT, Georgieva, L, Isles, AR, Chambert, KD, Richards, AL, et al. Analysis of copy number variations at 15 schizophrenia-associated loci. Br J Psychiatry 2014; 204: 108–14.
20Coe, BP, Witherspoon, K, Rosenfeld, JA, van Bon, BWM, Vulto-van Silfhout, AT, Bosco, P, et al. Refining analyses of copy number variation identifies specific genes associated with developmental delay. Nat Genet 2014; 46: 1063–71.
21Mansiaux, Y, Carrat, F. Detection of independent associations in a large epidemiologic dataset: a comparison of random forests, boosted regression trees, conventional and penalized logistic regression for identifying independent factors associated with H1N1pdm influenza infections. BMC Med Res Methodol 2014; 14: 99.
23Strobl, C, Hothorn, T, Zeileis, A. R J 2009; 1: 14–7.
24Kuhn, M. Building predictive models in R using the caret package. J Stat Softw 2008; 28: 1–26.
25Lee, SH, Goddard, ME, Wray, NR, Visscher, PM. A better coefficient of determination for genetic profile analysis. Genet Epidemiol 2012; 36: 214–24.
26Wang, X. Firth logistic regression for rare variant association tests. Front Genet 2014; 5: 187.
27Dudbridge, F. Power and predictive accuracy of polygenic risk scores. PLoS Genet 2013; 9: e1003348.
28Rees, E, Kendall, K, Pardiñas, AF, Legge, SE, Pocklington, A, Escott-Price, V, et al. Analysis of intellectual disability copy number variants for association with schizophrenia. JAMA Psychiatry 2016; 73: 963–9.
29Purcell, S, Cherny, SS, Sham, PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19: 149–50.
30Lally, J, Ajnakina, O, Di Forti, M, Trotta, A, Demjaha, A, Kolliakou, A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med 2016; 46: 3231–40.
31Meltzer, HY. Treatment-resistant schizophrenia–the role of clozapine. Curr Med Res Opin 1997; 14: 1–20.
32Kanahara, N, Yamanaka, H, Suzuki, T, Takase, M, Iyo, M. First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort. BMC Psychiatry 2018; 18: 274.
33Carbon, M, Correll, CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 2014; 16: 505–24.
34Hassan, AN, De Luca, V. The effect of lifetime adversities on resistance to antipsychotic treatment in schizophrenia patients. Schizophr Res 2015; 161: 496–500.
35Koutsouleris, N, Kambeitz-Ilankovic, L, Ruhrmann, S, Rosen, M, Ruef, A, Dwyer, DB, et al. Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: a multimodal, multisite machine learning analysis. JAMA Psychiatry 2018; 75: 1156–72.